Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with or without AZD6244 in wild-type BRAF advanced melanoma
ISRCTN89118367Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Oct 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Docetaxel + AZD6244 with Docetaxel + placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2010; status: completed.
02
Drugs
docetaxelselumetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on ISRCTN89118367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89118367.